| Literature DB >> 29127946 |
Kyu Seok Shim1, Min Hyung Kim1, Choong Nam Shim2, Minkyu Han3, In Seok Lim4, Soo Ahn Chae4, Sin Weon Yun4, Na Mi Lee1, Dae Yong Yi4, Hyery Kim5.
Abstract
BACKGROUND: Several studies have reported a seasonal trend in the diagnosis of childhood cancer suggesting seasonal factors such as infection. The present study aimed to analyze the diagnosis pattern of childhood malignant diseases using public health data, and to compare this pattern with seasonal viral infection trends.Entities:
Keywords: Childhood neoplasm; Seasonality; Time trend; Viral infections
Mesh:
Year: 2017 PMID: 29127946 PMCID: PMC7102810 DOI: 10.1016/j.canep.2017.11.003
Source DB: PubMed Journal: Cancer Epidemiol ISSN: 1877-7821 Impact factor: 2.984
International Classification of Diseases 10 for childhood cancer, aplastic anemia and myelodysplastic syndrome.
| Disease classification | ICD 10 codes |
|---|---|
| Aplastic anemia | D61.0–D61.9 |
| Acute lymphoblastic leukemia | C91.0, C91.3, C91.6, C91.7, C91.9 |
| Acute myeloid leukemia | C92.0, C92.3–C93.0, C94.2 |
| Bone tumor | C40.0, C41.0–C41.4, C41.8, C41.9 |
| Chronic myeloid leukemia | C92.1–C92.2 |
| Chronic myelomonocytic leukemia | C93.1 |
| Central nervous system tumor | C70.0, C70.1, C70.9, C71.0–C71.9, C72.0–C72.9 |
| Germ cell tumor | C56.0, C56.1, C56.9, C57.0, C57.3, C57.4, C57.7–C58.0, C60.0∼ |
| Hepatoblastoma | C22.2 |
| Hepatocellular carcinoma | C22.0 |
| Hodgkin’s lymphoma | C81.0, C81.1, C81.2, C81.3, C81.4, C81.7, C91.9 |
| Juvenile myelomonocytic leukemia | C93.3 |
| Myelodysplastic syndrome | C94.6, D46.0–D46.9 |
| Myelofibrosis/Myeloproliferative neoplasm | C94.5 |
| Neuroblastoma | C74 |
| Non-Hodgkin lymphoma | C82, C83, C84, C85, C86, C88.4 |
| Nasopharyngeal carcinoma | C11 |
| Retinoblastoma | C69.1, C69.2, C69.3, C69.4, C69.6, C69.9 |
| Renal tumor | C64 |
| Sarcoma | C49 |
ICD, International Classification of Diseases.
Fig. 1Redidual ACF correlogram and 95% confidence limits for newly diagnosed acute lymphoblastic leukemia, acute myeloid leukemia and total childhood malignant disease.
Fig. 2Monthly time series for numbers of newly diagnosed childhood cancer: (A) Longitudinal time series shows the variation in the total numbers of patients with newly diagnosed childhood malignant disease between September 2009 and December 2013; (B) Monthly stacked time series by year shows an apparent seasonal variation so that the annual lowest numbers were between September and November.
Monthly numbers of newly diagnosed patients with childhood malignant diseases in Korea.
| Mon | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Ave. |
| 2009 | 231 | 242 | 207 | 253 | 233 | ||||||||
| 2010 | 276 | 202 | 197 | 166 | 174 | 197 | 230 | 203 | 155 | 119 | 126 | 277 | 194 |
| 2011 | 204 | 196 | 218 | 165 | 155 | 157 | 219 | 186 | 138 | 108 | 135 | 210 | 174 |
| 2012 | 238 | 167 | 182 | 169 | 155 | 144 | 206 | 99 | 28 | 106 | 258 | 181 | 161 |
| 2013 | 227 | 176 | 160 | 143 | 149 | 155 | 186 | 128 | 48 | 80 | 153 | 201 | 151 |
| Ave. | 236 | 185 | 189 | 161 | 158 | 163 | 210 | 154 | 120 | 131 | 176 | 224 | 175 |
Mon, month; Ave., average.
Parameters of ARIMA models for newly diagnosed childhood malignant disease patients.
| Parameters | AA | ALL | AML | BT | CML | CNS | GCT | HBL | HL | MDS | NBL | NHL | NPca | RBL | RT | Sar | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| p | Nonseasonal AR | 0 | 3 | 1 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| q | Nonseasonal MA | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| P | Seasonal AR | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Q | Seasonal MA | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| d | Nonseasonal Diff | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 |
| D | Seasonal Diff | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Final model AIC | 347.14 | 367.99 | 282.83 | 180.18 | 202.73 | 14.03 | 379.62 | 341.56 | 212.84 | 190.37 | 216.00 | 88.43 | 233.77 | −55.90 | 253.03 | 334.05 | 173.42 | |
AA, aplastic anemia; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; AR, autoregressive; BT, bone tumor; CML, chronic myeloid leukemia; CNS, central nervous system tumors; Diff, difference; GCT, germ cell tumor; HBL, hepatoblastoma; HL, Hodgkin’s lymphoma; MA, moving average; MDS, myelodysplastic syndrome; NBL, neuroblastoma; NHL, Non-Hodgkin’s lymphoma; NPca, nasopharyngeal cancer; RBL, retinoblastoma; RT, renal tumor; Sar, sarcoma; AIC, Akaike’s Information Criterion
Seasonal difference analysis in newly diagnosed childhood malignancy by disease category.
| Season (months) | Spring (3, 4, 5) | Summer (6, 7, 8) | Autumn (9, 10, 11) | Winter (12, 1, 2) | |
|---|---|---|---|---|---|
| AA | 16.58 ± 4.25 | 19.00 ± 7.11 | 12.87 ± 8.31 | 19.69 ± 6.06 | 0.759 |
| ALL | 22.33 ± 5.37 | 20.42 ± 6.72 | 21.87 ± 11.72 | 28.54 ± 7.83 | 0.071 |
| AML | 9.58 ± 2.50 | 8.50 ± 3.26 | 9.67 ± 4.22 | 13.62 ± 2.99 | 0.004 |
| BT | 14.83 ± 3.66 | 14.83 ± 4.53 | 13.40 ± 8.10 | 18.38 ± 4.68 | 0.221 |
| CML | 2.00 [0.50; 2.50] | 3.00 [2.00; 3.50] | 2.00 [1.00; 2.00] | 3.00 [2.00; 3.00] | 0.108 |
| CNS | 35.42 ± 5.76 | 34.75 ± 10.06 | 29.73 ± 16.39 | 42.92 ± 13.76 | 0.305 |
| GCT | 17.08 ± 3.00 | 20.25 ± 6.31 | 11.67 ± 6.63 | 22.92 ± 6.16 | 0.359 |
| HBL | 2.50 [1.50; 4.00] | 2.50 [1.00; 3.50] | 3.00 [1.00; 4.00] | 1.00 [1.00; 3.00] | 0.77 |
| HL | 3.00 [1.50; 5.00] | 3.50 [2.00; 5.00] | 2.00 [1.00; 2.50] | 4.00 [3.00; 5.00] | 0.013 |
| MDS | 3.50 [1.50; 5.00] | 4.00 [3.00; 4.00] | 2.00 [1.00; 3.00] | 3.00 [2.00; 5.00] | 0.321 |
| NBL | 4.00 [2.50; 5.50] | 4.50 [3.00; 6.50] | 5.00 [3.50; 5.00] | 7.00 [6.00; 8.00] | 0.012 |
| NHL | 19.83 ± 4.78 | 21.25 ± 5.40 | 13.07 ± 6.97 | 22.54 ± 3.93 | 0.945 |
| NPca | 1.00 [1.00; 2.00] | 1.00 [0.00; 1.50] | 1.00 [0.00; 1.00] | 2.00 [1.00; 2.00] | 0.198 |
| RBL | 4.67 ± 2.06 | 4.58 ± 2.15 | 4.67 ± 3.83 | 7.00 ± 3.27 | 0.069 |
| RT | 4.58 ± 2.43 | 4.42 ± 2.78 | 4.07 ± 2.63 | 6.69 ± 3.66 | 0.12 |
| Sar | 6.58 ± 2.39 | 7.50 ± 3.97 | 6.20 ± 4.02 | 9.31 ± 3.61 | 0.149 |
| SUM | 169.42 ± 21.22 | 175.83 ± 39.42 | 142.27 ± 68.07 | 216.00 ± 35.97 | 0.119 |
AA, aplastic anemia; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BT, bone tumor; CML, chronic myeloid leukemia; CNS, central nervous system tumors; GCT, germ cell tumor; HBL, hepatoblastoma; HL, Hodgkin’s lymphoma; MDS, myelodysplastic syndrome; NBL, neuroblastoma; NHL, Non-Hodgkin’s lymphoma; NPca, nasopharyngeal cancer; RBL, retinoblastoma; RT, renal tumor; Sar, sarcoma; SUM, summation of all cases.
Values of the Granger causality test between the time series of childhood malignancy diagnosis and the time points of positive detection rates of virus, with <0.05 indicating significance (written in bold).
| A. Virus data & Diagnostic data after 1 month | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ds. | |||||||||||||||||
| Virus | AA | ALL | AML | BT | CML | CNS | GCT | HBL | HL | MDS | NBL | NHL | NPca | RBL | RT | Sar | SUM |
| HAdV | 0.735 | 0.203 | 0.791 | 0.052 | 0.847 | 0.423 | 0.251 | 0.201 | 0.125 | 0.912 | 0.602 | 0.316 | 0.112 | 0.907 | 0.243 | ||
| HPIV | 0.066 | 0.548 | 0.246 | 0.078 | 0.065 | 0.081 | 0.061 | ||||||||||
| HRSV | 0.570 | 0.083 | 0.327 | 0.486 | 0.286 | 0.355 | 0.706 | 0.812 | 0.102 | 0.208 | 0.528 | 0.928 | 0.515 | 0.070 | |||
| IFV | 0.244 | 0.617 | 0.449 | 0.785 | 0.440 | 0.546 | 0.810 | 0.696 | 0.439 | 0.745 | 0.494 | 0.585 | 0.649 | 0.532 | 0.651 | 0.672 | 0.633 |
| HCoV | 0.095 | 0.049 | 0.267 | 0.124 | 0.858 | 0.541 | 0.079 | 0.875 | 0.075 | 0.395 | 0.373 | 0.054 | 0.062 | 0.629 | 0.327 | 0.115 | |
| HRV | 0.627 | 0.976 | 0.962 | 0.389 | 0.591 | 0.896 | 0.665 | 0.856 | 0.449 | 0.279 | 0.749 | 0.916 | 0.190 | 0.508 | 0.062 | 0.528 | 0.933 |
| HBoV | 0.102 | 0.073 | 0.098 | 0.613 | 0.366 | 0.890 | 0.428 | 0.905 | 0.945 | 0.557 | 0.480 | 0.790 | 0.280 | 0.280 | 0.475 | 0.298 | 0.809 |
| Rota | 0.425 | 0.832 | 0.419 | 0.885 | 0.947 | 0.905 | 0.655 | 0.572 | 0.595 | 0.939 | 0.136 | 0.442 | 0.422 | 0.869 | 0.858 | 0.284 | 0.931 |
| Norovirus | 0.949 | 0.078 | 0.184 | 0.118 | 0.904 | 0.244 | 0.995 | 0.371 | 0.101 | 0.061 | 0.197 | 0.183 | 0.041 | 0.703 | 0.446 | 0.223 | |
| EntericAdenovirus | 0.996 | 0.172 | 0.620 | 0.970 | 0.992 | 0.889 | 0.492 | 0.127 | 0.828 | 0.501 | 0.831 | 0.468 | 0.762 | 0.256 | 0.766 | 0.521 | 0.803 |
| Astrovirus | 0.070 | 0.496 | 0.028 | 0.141 | 0.630 | 0.551 | 0.241 | 0.613 | 0.055 | 0.398 | 0.042 | 0.104 | 0.071 | 0.489 | 0.191 | 0.129 | |
AA, aplastic anemia; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BT, bone tumor; CML, chronic myeloid leukemia; CNS, central nervous system tumors; Ds., disease; GCT, germ cell tumor; HBL, hepatoblastoma; HL, Hodgkin’s lymphoma; MDS, myelodysplastic syndrome; NBL, neuroblastoma; NHL, Non-Hodgkin’s lymphoma; NPca, nasopharyngeal cancer; RBL, retinoblastoma; RT, renal tumor; Sar, sarcoma; Sum, summation of all cases.
P-values < 0.05 were considered as indicating causality.